AstraZeneca: Positive TEZSPIRE results from the eosinophilic esophagitis phase III CROSSING trial were announced at the European Joint Gastroenterology Week, including symptom improvement, histology, and endoscopic remission.

Zhitongcaijing · 2d ago
AstraZeneca: Positive TEZSPIRE results from the eosinophilic esophagitis phase III CROSSING trial were announced at the European Joint Gastroenterology Week, including symptom improvement, histology, and endoscopic remission.